(10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c][1]benzopyran-1-ol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: (10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c][1]benzopyran-1-ol
• 英文别名: (10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
• 化学式: C₂₅H₃₈O₃
• 分子量: 386.6
• InChiKey: SSQJFGMEZBFMNV-XJDOXCRVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• High enantiomeric purity dexanabinol for pharmaceutical compositions
  申请人：Aviv Haim

  公开号：US20070060636A1

  公开（公告）日：2007-03-15

  The present invention relates to a synthetic cannabinoid, dexanabinol, of enantiomeric purity in excess of 99.90%, or to a pharmaceutically acceptable salt, ester or solvate of said compound. The present invention also relates to pharmaceutical grade compositions comprising said compound of high enantiomeric purity, and uses thereof for prevention and treatment of neurological disorders, chronic degenerative diseases, CNS poisoning, cognitive impairment, inflammatory diseases or disorders, autoimmune diseases or disorders, pain, emesis, glaucoma and wasting syndromes.

  本发明涉及一种合成大麻素，即左旋丙氨酸酯，其对映异构体纯度超过99.90％，或该化合物的药学上可接受的盐，酯或溶剂。本发明还涉及包含高对映异构体纯度的该化合物的制药级组合物，以及用于预防和治疗神经系统疾病，慢性退行性疾病，中枢神经系统中毒，认知障碍，炎症性疾病或紊乱，自身免疫疾病或紊乱，疼痛，呕吐，青光眼和消耗综合征的用途。
• [EN] PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF<br/>[FR] DÉRIVÉ DE PHOSPHAMIDE, SON PROCÉDÉ DE FABRICATION ET SES UTILISATIONS<br/>[ZH] 一种磷酰胺衍生物及制备方法和用途
  申请人：SICHUAN HAISCO PHARMACEUTICAL CO LTD

  公开号：WO2017133517A1

  公开（公告）日：2017-08-10

  公开了一种磷酰胺衍生物及制备方法和用途。特别公开了一种通式(I)所示化合物及其药学上可接受的盐或立体异构体 (I)，其中，G、L、Q、s如说明书中所定义。
• A DRUG SCREENING PLATFORM FOR RETT SYNDROME
  申请人：The Regents of the University of California

  公开号：EP2841067A2

  公开（公告）日：2015-03-04
• Novel Neuroprotective Compounds and Uses Thereof
  申请人：Gozin Michael

  公开号：US20100144868A1

  公开（公告）日：2010-06-10

  Disclosed are novel hybrid compounds having a fullerene core residue, one or more bioavailability enhancing moieties and one or more glutamate receptor ligand residues, whereby the bioavailability enhancing moiety allow the compound to reach an effective concentration in physiological media and pass the blood-brain barrier, as defined in the specification. Also disclosed are pharmaceutical compositions containing these hybrid compounds and uses thereof as antioxidants and/or neuroprotective agents for the treatment of medical conditions associated with oxidative stress and/or neural damage, such as, for example, neurological diseases, disorders and trauma, and hence in the treatment of CNS-associated diseases, disorders and trauma, as well as to uses thereof as antiviral, antibacterial, antiglycemic, antiarrhythmic, antidepressant and antitumor agents.
• [EN] CANNABINOID FOR THE TREATMENT OF NEURONAL DAMAGE IN DIABETIC PATIENTS<br/>[FR] CANNABINOÏDE POUR LE TRAITEMENT DES LÉSIONS NEURONALES CHEZ LES PATIENTS DIABÉTIQUES
  申请人：YISSUM RES DEV CO

  公开号：WO2008129529A2

  公开（公告）日：2008-10-30

  [EN] The invention provides for the use of an effective amount of at least one cannabinoid selected from the group consisting of HU-210 and Tetrahydrocannabinol (THC) for the manufacture of a pharmaceutical composition for alleviating neuronal damage due to hyperglycemia, or for treating neuronal damage in a diabetic subject, wherein HU-210 is the (+)-1,1-dimethylheptyl analog of 7-hydroxy-delta-6- tetrahydrocannabinol of the formula (I).
  [FR] La présente invention concerne l'utilisation d'une quantité effective d'au moins un cannabinoïde sélectionné dans un groupe consistant de HU-210 et de tétrahydrocannabinol (THC) pour la fabrication d'une composition pharmaceutique pour l'atténuation de la lésion neuronale due à l'hyperglycémie, ou pour le traitement de la lésion neuronale chez un sujet diabétique, dans laquelle HU-210 est l'analogue (+)-1,1-diméthylheptyl du 7-hydroxy-delta-6- tétrahydrocannabinol de formule :